Company
Raffles Medical Group Ltd
SGX:BSL
An integrated private healthcare provider, not a longevity biotech. Founded 1976 and headquartered at Raffles Hospital, 585 North Bridge Road, Singapore, it runs family medicine clinics, specialist centres, hospitals, dental and Chinese medicine practices, insurance and healthcare products across Singapore, China, Vietnam, Cambodia and Japan. The longevity-relevant part is a preventive and chronic-care line rather than the group as a whole: health screening packages, an executive medical centre, statutory health checks, corporate health programmes covering more than 7,000 corporate clients, and chronic disease management delivered through its primary care network. That makes it the closest SGX-listed proxy for a clinical healthspan business, but the revenue base is conventional hospital and clinic services, and the company makes no ageing-biology or lifespan-extension claim. Treat it as delivery infrastructure for preventive medicine, not as an intervention developer.
At a glance
- Listing
- SGX:BSL
- Category
- Healthtech
- Headquarters
- Singapore
- Market cap
- Approximately SGD 1.73 billion (17 July 2026, share price SGD 0.94)
Thesis
Why it is in this universe
- Category
- Healthtech
- Market
- Singapore
- Recent inflection
- FY2025 (year ended 31 December 2025) results released 22 February 2026: revenue of SGD 765.6 million, up 1.8% on FY2024's SGD 752.4 million, with net income of SGD 70.6 million, up 13.4% on SGD 62.2 million, so margin expansion rather than top-line growth drove the year. The stock nonetheless traded near its 52-week low of SGD 0.90 in July 2026. Source: stockanalysis.com SGX:BSL financials and quote pages, and the SGinvestors announcement calendar showing the 22 February 2026 full-year results release.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | SGX |
| Ticker | SGX:BSL |
| Secondary listing | None |
| Market cap | Approximately SGD 1.73 billion (17 July 2026, share price SGD 0.94) |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Singapore
- Website
- links.sgx.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
FY2025 (year ended 31 December 2025) results released 22 February 2026: revenue of SGD 765.6 million, up 1.8% on FY2024's SGD 752.4 million, with net income of SGD 70.6 million, up 13.4% on SGD 62.2 million, so margin expansion rather than top-line growth drove the year. The stock nonetheless traded near its 52-week low of SGD 0.90 in July 2026. Source: stockanalysis.com SGX:BSL financials and quote pages, and the SGinvestors announcement calendar showing the 22 February 2026 full-year results release.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- SGX corporate information: Raffles Medical Group Ltd (ISIN SG1CH4000003, incorporated Singapore, Mainboard-listed since 10 July 2000) · Singapore Exchange
- About Raffles Medical Group: services, health screening and wellness, footprint across Singapore, China, Japan, Vietnam and Cambodia · Raffles Medical Group
- Raffles Medical Group (SGX:BSL) stock price and market capitalisation · StockAnalysis
- Raffles Medical Group (SGX:BSL) FY2025 income statement · StockAnalysis
- Raffles Medical latest announcements (SGX:BSL), FY results released 22 February 2026 · SGinvestors.io
Every entity profile on variis is sourced. Not investment advice.